Breast Cancer
Conference Coverage
Women with HER2+ metastatic breast cancer are living longer
Overall survival improved 5.6% each year among over 5,000 patients in the study.
Conference Coverage
Treating bone loss ups survival for breast cancer patients
Findings suggest a trend toward reduction in contralateral breast cancer in the treatment group.
Conference Coverage
Pembrolizumab before surgery improves survival in early triple negative breast cancer
Treatment shifts residual cancer burden to lower categories.
Conference Coverage
New treatment outperforms chemo in HER2-low breast cancer
The results may cause clinicians to reconsider how they define HER2 expression in breast cancer.
Conference Coverage
New treatment meets unmet need in breast cancer
Expert calls advance incremental, but clinically important for women with HR positive/HER2 negative breast cancer.
Latest News
Green tea ingredient shows promise for preventing severe radiation dermatitis
EGCG has the potential to become a new skin care option for patients receiving radiotherapy, the investigators believe.
From the Journals
Neoadjuvant denosumab ineffective in breast cancer
Trial returns a negative result for the RANKL inhibitor, but identifies favored schedule for nab-paclitaxel.
From the Journals
‘Unlimited’ cancer costs: The Medicare Part D dilemma
Many patients with cancer who rely on Medicare Part D face an impossible choice: “Your money or your life.”
From the Journals
Time-restricted eating may reduce CVD risk after breast cancer
“You can see how that is much easier for a doctor to explain to a patient than trying to explain how to meet the physical activity guidelines each...
From the Journals
Metformin bombs in breast cancer in landmark trial
“Metformin is not effective against the most common types of breast cancer and any off-label use [of] this drug for the treatment of these common...
From the Journals
Sex hormones linked to breast cancer in men
Finding could point to a role for sex hormones, but more work needs to be done.